The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Vaxcyte. The maintained price target of $70 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor interest and a potential rise in the stock's price in the short term.